Rosalyn Juergens

Research Interests

Explore related searches

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (20)

Collaborators (6)

Luis Puig

University of Barcelona

Delvys Rodriguez-Abreu

Universidad de Las Palmas de Gran Canaria

Marcus Butler

University Health Network

Keith Eaton

Fred Hutchinson Cancer Research Center

UNITED STATES

Hossein Borghaei

Professor and Chief, Thoracic Oncology

Fox Chase Cancer Center

UNITED STATES

Geoffrey Liu

University of Toronto

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Rosalyn Juergens

Research Interests

Explore related searches

Contact this professor

Articles (20)

Collaborators (6)

Luis Puig

Delvys Rodriguez-Abreu

Marcus Butler

Keith Eaton

Hossein Borghaei

Geoffrey Liu

Make your next move.

Rosalyn Juergens

Research Interests

Explore related searches

Contact this professor

Articles (20)

Systemic treatment of immune checkpoint inhibitor‐induced psoriasis: Inference‐based guidance

Canadian Perspectives Revisited: Consensus on the management of ALK-rearranged NSCLC

Leptomeningeal carcinomatosis presenting as catatonia

A biomarker-directed, multi-center phase II/III study of ctDNA molecular response adaptive immuno-chemotherapy in patients with non-small cell lung cancer (BR.36).

MK-1084 for KRAS G12C-mutated (mut) metastatic non–small-cell lung cancer (mNSCLC): Results from KANDLELIT-001.

Xevinapant plus avelumab in advanced solid tumours, with a dose expansion in advanced non-small-cell lung cancer: exploratory biomarker, safety and efficacy analyses from an open-label, nonrandomised phase Ib study

Effects of cannabinoids on immune checkpoint inhibitor response: CCTG pooled analysis of individual patient data

A Phase II Study of Neoadjuvant Opnurasib KRAS G12C Inhibitor in Patients With Surgically Resectable Non-Small Cell Lung Cancer (CCTG IND.242A): A Substudy of the IND.242 Platform Master Protocol

A Poor Prognostic ALK Phenotype: A Review of Molecular Markers of Poor Prognosis in ALK Rearranged Nonsmall Cell Lung Cancer

The continually evolving landscape of novel therapies in oncogene-driven advanced non-small-cell lung cancer

SAPPHIRE: phase III study of sitravatinib plus nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer

Modern era systemic therapies: Expanding concepts of cure in early and locally advanced non‐small cell lung cancer

Treatment patterns and outcomes in KRASG12C ‐positive advanced NSCLC patients previously treated with immune checkpoint inhibitors: A Canada-wide real-world, multi-center, retrospective cohort study

A biomarker-directed, multi-center phase II/III study of ctDNA molecular response adaptive immuno-chemotherapy in patients with non-small cell lung cancer.

Quality of life (QoL) benefits following 177Lu-DOTATATE therapy in patients (pts) with 68Ga-DOTATATE PET positive primary site agnostic neuroendocrine tumors (NET).

What is a bad ALK? A scoping review of molecular markers of poor prognosis.

Access to Oncology Medicines in Canada: Consensus Forum for Recommendations for Improvement

44O Updated results from a phase I study evaluating the KRAS G12C inhibitor MK-1084 in solid tumors and in combination with pembrolizumab in NSCLC

A phase 1, open-label, multicenter study evaluating MK-1084 as monotherapy and in combination with other therapies in patients with KRAS G12C mutant advanced solid tumors.

Overcoming Resistance Mechanisms to Immune Checkpoint Inhibitors: Leveraging the Anti-Tumor Immune Response

Collaborators (6)

Luis Puig

Delvys Rodriguez-Abreu

Marcus Butler

Keith Eaton

Hossein Borghaei

Geoffrey Liu

Make your next move.